SCHEMBL6323612

SCHEMBL6323612

CNC(=O)[C@@H](Cc1ccccc1F)N(C)C(=O)[C@@H](COCc1ccccc1)N(C)C(=O)c1cccc(C(C)N)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.36
BACE1 P56817 2/20 0.36
CFD P00746 1/20 0.35
F11 P03951 1/20 0.35
TPSB2 P20231 1/20 0.35
PTPN1 P18031 2/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
MMP9 P14780 2/20 0.33
MMP2 P08253 1/20 0.33
MMP8 P22894 1/20 0.33
TACR1 P25103 1/20 0.33
MMP14 P50281 1/20 0.33
SLC7A5 Q01650 1/20 0.33
CTSL P07711 2/20 0.33
CTSB P07858 2/20 0.33
CTSS P25774 2/20 0.33
KMT2A Q03164 1/20 0.33
MME P08473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318599 0.92 BACE1 (0.37) BACE1CFDF11TPSB2BACE2
SCHEMBL6318816 0.90 PTPN1 (0.37) BACE1PTPN1SLC7A5CTSLCTSB
SCHEMBL6324012 0.87 MMP1 (0.40) TACR1KMT2A
SCHEMBL6325998 0.87 ADAM17 (0.36) BACE1BACE2CTSSKMT2AMME
SCHEMBL6325315 0.86 KCNA5 (0.37) KCNA5BACE1CFDF11TPSB2
SCHEMBL6318694 0.84 PTPN1 (0.38) KCNA5PTPN1MMP9MMP8
SCHEMBL6326644 0.82 MMP2 (0.37) KCNA5MMP9MMP2MMP8TACR1
SCHEMBL6324114 0.81 LOXL2 (0.39) BACE1SLC7A5CTSLCTSBCTSS
SCHEMBL6323305 0.79 ALDH1A1 (0.40) BACE1BACE2SLC7A5MME
SCHEMBL6318940 0.79 MMP12 (0.38) BACE1MMP9MMP2MMP8TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US claimed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US claimed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP claimed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO claimed
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 KCNA5 1967/4885BACE1 528/4885CFD 1108/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR KCNA5 2171/4885BACE1 567/4885CFD 1051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.